Clinical trial

Phase 2 Trial of Bevacizumab in Combination With Pemetrexed

NCT00227019

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2006-03-01

PhasePHASE2

Study timeline

Study start (unknown)2006-03-01Date precision: month

Registry last updated2017-03-06

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Non-small Cell Lung Cancer (NSCLC)unresolved

Lung Cancerunresolved

Neoplasm Metastasisunresolved

Interventions

BevacizumabDRUG · verified · RxNorm: bevacizumab

PemetrexedDRUG · verified · RxNorm: pemetrexed

Vitamin B12DRUG · verified · RxNorm: vitamin B12

DexamethasoneDRUG · verified · RxNorm: dexamethasone

Sponsors & collaborators

Heather Wakeleelead sponsor

Eli Lilly and Companycollaborator

Genentech, Inc.collaborator

Mapped research locations

Chapel HillNorth Carolina, United States1 StanfordCalifornia, United States1 LebanonNew Hampshire, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00227019 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.